Literature DB >> 27276405

Living and working in spite of antiretroviral therapies: strength in chronicity.

Matteo Carlo Alcano1.   

Abstract

This article is a reflection on the relationship between antiretroviral therapies and work. It is concerned with the impact of biomedical protocols and biotechnologies on the 'lifeworlds' of a small group of seropositive men employed in the construction industry in Milan. Construction workers stand out as a category with specific issues because of their physically demanding jobs and are more subject to the potentially damaging physical consequences of antiretroviral therapies, as data suggest. The article is focused on biomedical rationalities and technologies and interrogates the forms of knowledge and the practices that contribute to reshaping seropositive individuals as 'biological and therapeutic citizens'. At the same time, the relationship between identity and health technologies is explored, examining the individual trajectories and strategies displayed by construction workers in order to cultivate their own ideas of personhood and conception of identity. How they rethink their presence within the work environment is shown in light of drug regimens and through a creative manipulation of antiretroviral therapies.

Entities:  

Keywords:  HAART; HIV; biotechnologies; citizenship; inequities; work

Year:  2009        PMID: 27276405     DOI: 10.1080/13648470902940630

Source DB:  PubMed          Journal:  Anthropol Med        ISSN: 1364-8470


  2 in total

1.  'Dented' and 'resuscitated' masculinities: the impact of HIV diagnosis and/or enrolment on antiretroviral treatment on masculine identities in rural eastern Uganda.

Authors:  Godfrey E Siu; Daniel Wight; Janet Seeley
Journal:  SAHARA J       Date:  2014

2.  How a masculine work ethic and economic circumstances affect uptake of HIV treatment: experiences of men from an artisanal gold mining community in rural eastern Uganda.

Authors:  Godfrey E Siu; Daniel Wight; Janet Seeley
Journal:  J Int AIDS Soc       Date:  2012-06-14       Impact factor: 5.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.